New research linking dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat type 2 diabetes to an increased risk for inflammatory bowel disease (IBD) is prompting investigators to urge monitoring ...

Researchers noted fDPP-4 discriminated clinical activity from remission with areas under the curve of 0.8 (95% CI, 0.68-0.93) and 0.76 (95% CI, 0.58-0.94) in patients with UC and CD, respectively.

Most patients in the DPP-4 cohort received sitagliptin (94.6%), although saxagliptin and vildagliptin were also prescribed in 5.4% and less than 0.1% of patients, respectively.

Results showed that DPP-4 inhibitors yielded 0.42 cases of bullous pemphigoid per 1,000 person-years compared with 0.31 cases per 1,000 person-years for sulfonylureas (HR = 1.42; 95% CI, 1.17-1.72).

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape. Cite this: Generic DPP-4 Inhibitors Would Be a 'Shot in the Arm' - Medscape - Feb 08 ...

Data presented covered 2014 to 2016, and included 17,551 matched pairs of empagliflozin and DPP-4 inhibitor users. Patients’ average age was 58.7 years and nearly 25% in each group had a history ...

Across a broad swath of patients, short-term use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor appears to reduce the risk of major adverse cardiovascular events, most notably cardiovascular ...

Infographic: Incretins and More: The Physiology of DPP-4 —DPP-4 is known primarily for its role in glucose homeostasis. But that's not the whole story.

This elevated risk equated to a bullous pemphigoid incidence rate of 0.42 among DPP-4 inhibitor users versus 0.31 for sulfonylurea users per 1,000 person-years, they wrote in JAMA Dermatology.